Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Displaying 1 to 2 of 46 Posts . Displaying 2 of Posts . Page of 23 . Go To Page: . Per Page: . . . View All Sort By: .

Lilly to Present 5-Year Sustained Efficacy and Safety Results for TaltzĀ® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz® (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to receive Taltz maintained high levels of skin clearance with no unexpected safety...

Read More

Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments

Corticosteroid therapy is regarded as first-line therapy for treating mild psoriasis and recalcitrant lesions. Members of the IPC Topical Therapies Working Group reviewed available international topical corticosteroids guidelines in order to understand current information and to identify areas that would benefit from greater practical guidance for dermatologists.

Read More
UPCOMING EVENT

Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas

Monday, june 10, 2019
1:30 – 4:30 pm
milan, italy
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

This website uses cookies. Please ensure your cookies are enabled. 
OK